Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The.
Speaker 2: Stock Movers Report, your roundup of companies making moves in
Speaker 2: the stock market, harnessing the power of Bloomberg Data.
Speaker 3: I'm Carol Masser along with Tim Stentemick. Let's get to
Speaker 3: some stocks on the move. And to be fair, we
Speaker 3: do mention Cerebras because it is an IPO, the biggest
Speaker 3: one of the year, and the stock is up seventy
Speaker 3: four percent as we speak, but it was up as
Speaker 3: much as one hundred and eight percent. It was an
Speaker 3: oversubscribed IPO, and yeah, please, it's part of the AI
Speaker 3: story and the semiconductor story. So interesting, interesting, interesting. So
Speaker 3: ticker is CBRS. Let's go to another technique.
Speaker 1: Yeah, it was one hundred and eighty five dollars IPO price. Okay,
Speaker 1: that's what the number I was going for.
Speaker 3: Okay, sorry, I couldn't read your mind. Let's bring it up.
Speaker 3: It's been a long WEEKO.
Speaker 1: You have to be with me for two more hours.
Speaker 3: I know we've realized in the last twenty four hours.
Speaker 3: We went to a breakfast together, we did a show together,
Speaker 3: we went to kind of a dinner thing together.
Speaker 1: And then I was like we gotta go.
Speaker 3: He's like, I don't want to see you for a while.
Speaker 3: I do want to see avalon Pronell. She's Blimberg News
Speaker 3: Equities Report, and she joins us in studio with stocks.
Speaker 4: Oh the move.
Speaker 3: Let's talk about Cisco absolutely.
Speaker 4: That's ticker CSCO currently up about thirteen percent to hit
Speaker 4: a record intraday high. That's after reporting third quarter results
Speaker 4: that very much came above expectations and also boosting its
Speaker 4: full year outlook. Worth noting that it did also announce
Speaker 4: job cuts as it continues to focus on sending those
Speaker 4: resources towards AI. But Morgan Stanley said that their AI
Speaker 4: preparation is really helping the company hit a growth rate
Speaker 4: that they haven't achieved in fifteen years.
Speaker 3: That's amazing, just soaring. And there was a period go
Speaker 3: back a little bit where I think people were concerned
Speaker 3: they were going to miss the whole AI craze, and
Speaker 3: here they.
Speaker 4: Are definitely proving some people wrong.
Speaker 3: Yeah, exactly, exact, exactly where should we go next?
Speaker 4: Forward? A different name that has also been kind of
Speaker 4: popping on the AI trade that you wouldn't expect. That's
Speaker 4: ticker f It's currently up about five point six percent
Speaker 4: and on pace to notch it's best two day gains
Speaker 4: since twenty twenty. That's partially because it's extending those gains
Speaker 4: as investor enthusiasm for AI and more specifically, the automaker's
Speaker 4: pivot toward energy storage builds. Part of that hype is
Speaker 4: because of Morgan Stanley's great note yesterday, very bullish, saying
Speaker 4: that the automaker's energy storage business could make a deal
Speaker 4: with Hyperscalers soon, and we already know that's very much
Speaker 4: involved with AI.
Speaker 1: There are some analysts who are cautioning that the hype
Speaker 1: around this energy storage a business could be short lived.
Speaker 1: The stock is vulnerable to a quick reversal, but in
Speaker 1: some have warned that the rally seems more like momentum
Speaker 1: driven than a sober reevaluation of its prospects. That said,
Speaker 1: this two day increase is pretty remarkable.
Speaker 4: Exactly, and Celia is putting a lot of money towards
Speaker 4: that as well.
Speaker 3: Sounds like we could do a debate right to these
Speaker 3: analysts right in terms of what they're thinking, which is
Speaker 3: which is really interesting, but gosh, Ford, we're just a
Speaker 3: different narrative that we're talking.
Speaker 1: She wants to go biotech.
Speaker 3: We have to how do you.
Speaker 4: Say this company region x Bio, that's ticker rgn X.
Speaker 4: It is sinking thirty seven percent most inter day on record.
Speaker 4: Part of that is because they reported that two of
Speaker 4: their patients who were taking this gene therapy had significant
Speaker 4: complications or side effects. And while the goals were met
Speaker 4: for this drug it's treating a very deadly muscular disease,
Speaker 4: investors remain skittish. Serepta is also treating the same thing,
Speaker 4: and they had a lot of issues last year, as
Speaker 4: you guys remember, and so there's a lot of questions
Speaker 4: of will just be able to make that accelerated approval
Speaker 4: or not.
Speaker 2: This stock mover's report from Bloomberg Radio. Check back with
Speaker 2: us throughout the day for the latest roundup of companies
Speaker 2: making news on Wall Street and for the latest market
Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
Speaker 2: Bloomberg dot com, and on Apple CarPlay and Android Auto
Speaker 2: with the Bloomberg Business app.